NASDAQ:AGIO - Agios Pharmaceuticals Stock Price, Forecast & News

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Agios Pharmaceuticals Inc (NASDAQ:AGIO) posted its earnings results on Thursday, February, 13th. The biopharmaceutical company reported ($1.60) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.72) by $0.12. The biopharmaceutical company earned $35.44 million during the quarter, compared to the consensus estimate of $33.72 million. Agios Pharmaceuticals had a negative net margin of 348.96% and a negative return on equity of 73.42%. The firm's quarterly revenue was up 18.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.58) earnings per share. View Agios Pharmaceuticals' Earnings History.

Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for Agios Pharmaceuticals.

11 analysts have issued 1-year price targets for Agios Pharmaceuticals' shares. Their forecasts range from $49.00 to $79.00. On average, they anticipate Agios Pharmaceuticals' share price to reach $64.56 in the next year. This suggests a possible upside of 30.0% from the stock's current price. View Analyst Price Targets for Agios Pharmaceuticals.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agios Pharmaceuticals.

Headlines about AGIO stock have been trending neutral this week, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Agios Pharmaceuticals earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Agios Pharmaceuticals.

Some companies that are related to Agios Pharmaceuticals include Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Mylan (MYL), Beigene (BGNE), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Ascendis Pharma A/S (ASND) and The Medicines (MDCO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Celgene (CELG), Gilead Sciences (GILD), bluebird bio (BLUE), Alibaba Group (BABA), Intercept Pharmaceuticals (ICPT), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), NVIDIA (NVDA) and Micron Technology (MU).

Agios Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (14.99%), Capital International Investors (7.70%), State Street Corp (3.20%), First Trust Advisors LP (2.60%), Farallon Capital Management LLC (2.12%) and ArrowMark Colorado Holdings LLC (1.88%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, David Scadden, Jacqualyn A Fouse, John Maraganore, Kaye I Foster-Cheek, Scott Biller and Steven L Hoerter. View Institutional Ownership Trends for Agios Pharmaceuticals.

AGIO stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Capital International Inc. CA, Capital Bank & Trust Co, Alliancebernstein L.P., Casdin Capital LLC, Handelsbanken Fonder AB, Capital International Investors and Rhenman & Partners Asset Management AB. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, Christopher Bowden, Scott Biller and Steven L Hoerter. View Insider Buying and Selling for Agios Pharmaceuticals.

AGIO stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Perceptive Advisors LLC, First Trust Advisors LP, Bank of America Corp DE, Marshall Wace LLP, Geode Capital Management LLC, UBS Asset Management Americas Inc. and Cadian Capital Management LP. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Corp /De/ Celgene, David P Schenkein, David Scadden and Jacqualyn A Fouse. View Insider Buying and Selling for Agios Pharmaceuticals.

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGIO stock can currently be purchased for approximately $49.67.

Agios Pharmaceuticals has a market capitalization of $3.40 billion and generates $117.91 million in revenue each year. The biopharmaceutical company earns $-411,470,000.00 in net income (profit) each year or ($6.86) on an earnings per share basis. Agios Pharmaceuticals employs 482 workers across the globe.View Additional Information About Agios Pharmaceuticals.

The official website for Agios Pharmaceuticals is http://www.agios.com/.

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]